February 1, 2011

Strengthening your value analysis process

By: OR Manager
Share

Is your value analysis process as strong as it could be? Value analysis is a key link in building a supply chain strong enough to stand up to today’s cost management challenges.

Check your process against these success factors, outlined by Thomas Skorup, MBA, FACHE, vice president of the Applied Solutions Group at ECRI Institute, a nonprofit organization based in Plymouth Meeting, Pennsylvania, that researches health care technology and services.

Also consider qualities of top supply chain performers identified by the Health Management Academy, an educational forum for health care executives, in a study (sidebar). A caveat: Value analysis has to be about more than costs.

“The concept of value analysis has always been to look at the full value proposition primarily for new supplies,” Skorup says. But too often, when physicians hear “value analysis,” they think it only means the hospital is trying to save money.

“Value analysis is not just about money. It’s looking at whether a new product will optimize clinical care by either improving care or providing the same level of care at a lower cost and thus benefiting the whole organization.”

Here are criteria to evaluate to see if your value analysis process is as strong as it could be.

Does surgical services have its own value analysis team?

Either hospitalwide or dedicated surgical services value analysis teams can work well. In any case, Skorup says, surgical services should at least have its own value analysis subcommittee.

“Surgery is such a huge driver of the supply chain that having it blended with a medical-patient care value analysis process is too much. It’s a different audience,” he says. Even a surgical services value analysis team can sometimes be too broad, resulting in agendas that are too long.

“If you’re a specialist attending a meeting, and only 15 minutes applies to you, you’re probably going to lose interest,” he points out.

Some organizations create subteams for areas such as orthopedics, spine and biologics, endovascular services, and so forth. But coordination is important.

“You want specialization when appropriate, but you don’t want decisions so decentralized that 2 different committees might approve competing products,” he says.

Are the right players on the team?

For value analysis to be effective, clinicians need to have a central role. “You want the decision point to be as close to the clinicians as possible,” he says.

That means surgeons and perioperative nurse coordinators should be key players on the surgical services value analysis team (VAT). Otherwise, it’s difficult for the team to talk through the clinical merits of a product for which a physician is a strong advocate.

Ideally, the value analysis team is co-chaired by a physician and a vice president or director-level administrator. “That sends the message that the decision makers are there, and that keeps people participating,” he says.

“It’s nice if the physician co-chair is also a member of the OR Committee and can provide a conduit,” he adds. Then there is the option to take decisions that need deeper discussion to the OR Committee.

Some organizations pay physicians for participation on the VAT.

“That shows you respect their time and recognize their time is valuable. They come to meetings with a very different posture,” he says.

Other VAT members might include the OR manager, RN team leaders, a supply chain or materials management specialist, a finance department representative who understands charging and reimbursement, an infection preventionist, a nurse educator, and a patient safety specialist. In one value analysis program Skorup is familiar with, a nurse educator and clinical engineer have to sign off on an educational plan before a new product can be purchased to be sure the staff has been properly prepared on the new equipment.

Is your process easy to navigate?

Ask yourself: Does the process make it easy for the physicians to do the right thing? Are decisions made in a timely manner?

Most VATs have standard product evaluation forms, which Skorup says “are a great starting point.”

He suggests 2 forms. One is the product request form filled out by the requesting clinician. This form includes the product’s purpose, units of measure, estimated volume per year, Food and Drug Administration status, whether it contains latex, whether it is eligible for additional reimbursement, and so forth. He also recommends disclosure of conflict of interest by the person requesting the product.

“Transparency of this information is becoming more important,” he says.

The second form is for information supplied by the vendor.

“In some cases, I’ve seen the form ask the vendor to certify whether there is anyone in the hospital the company is paying money to,” he says. A physician’s financial relationship to a company is not a “hard stop,” but provides the VAT with additional information for evaluating the request.

Have you committed adequate resources?

A successful value analysis program hinges on having enough information to make informed decisions. “Typically, these teams are severely under-resourced,” he says.

Ideally, skill sets of VAT members are aligned with the information needed. The supply chain staff, for example, usually gathers product information, including the purpose, expected volume, group purchasing contracts, the cost, and related information. The finance department contributes reimbursement information.

“It’s important to have the right finance person on the team to have the clout to get a quick response,” he says.

Researching a product’s clinical merits can be the biggest challenge. “Perfect evidence often is not there to directly compare products,” Skorup says.

VAT members should have a basic grounding in evaluating research, including basic study design and sources of financial support for studies. For example, was the study supporting a product a randomized controlled clinical trial or a small case series? Was the study published in a peer-reviewed journal? Did the researchers receive funding from the product’s vendor? (Some studies funded by companies may not appear in print because they do not have positive outcomes.)

In the future, more evidence may be available through comparative effectiveness research funded by the federal stimulus package, but that will take several years.

Some organizations like ECRI Institute offer analyses of the published literature, which identifies what evidence there is and how robust it is.

“Just understanding what is there and not there is helpful,” Skorup notes.

Another tactic he suggests is to ask the sales personnel for the single best study available on the product. If that study isn’t strong, that tells you something.

Don’t overlook investigating potential safety problems when evaluating products. VAT members may not realize their organization already belongs to ECRI Institute’s Health Devices Alerts service, which provides that information. Simply searching Google and PubMed for the product name isn’t enough, Skorup advises.

Are meetings focused?

Strive to keep meetings to about 1 hour and follow an agenda. “I’ve seen agendas that are just a spreadsheet listing products to be discussed, and the committee goes through the list until it is finished. That’s not an agenda, and people get turned off,” he says.

He advises doing as much research as possible in advance and sharing results so VAT members can review the information before meetings. Otherwise, a lot of time is spent during the meeting just reviewing information collected.

“Time in the meeting should be spent in discussion, not ramping up for the discussion,” he says.

If meetings routinely stretch beyond 1½ hours, that probably means meetings need to be conducted differently, or subcommittees may be needed.

How should VAT decisions be made? Skorup advocates consensus rather than majority vote.

“You want the value analysis team to be the ‘eyes and ears’ of a cultural change to evidence-based decision making,” he says. “You don’t want a committee member to say later, ‘I didn’t vote for that.'”

The decision may be to have the physicians trial a new product. If so, he suggests that the trial should be structured, conducted in a defined timeframe, and include a form to gather responses from clinicians to guide the team in making a final decision.

Do you have a strong vendor management policy?

Though generally not part of the value analysis process, a strong vendor policy prevents products from finding their way into inventory without going through the value analysis process.

“The senior administration has to support the policy,” Skorup adds. “Usually, the policy states that if a device doesn’t go through the value analysis process, the hospital won’t pay for it. That’s easy to say, but when the senior vice president enforces it once, the message gets across.” The policy, of course, needs to include an expedited process for products needed for one-time use on short notice. Typically, this includes approval by the chief of surgery and a senior vice president that is documented as a one-time exemption. Otherwise, the organization will not pay for the device.

Do you do a look-back on decisions?

To close the loop on product decisions, the value analysis process should include a retrospective review. Did the product achieve the expected results? That means the reason for the approval needs to be documented at the time the decision was made. Was the product approved for cost reduction or clinical improvement reasons?

“That review starts at the decision point,” Skorup says. “If you don’t document why you approved the item, then you can’t look back to see if that objective was reached.”

Success factors

Successful value analysis programs have these characteristics, according to Thomas Skorup of ECRI Institute:

A defined process

The value analysis team follows a defined process and uses standard forms endorsed by the OR’s governing body.

“That way, it’s hard to buck the system. And if it’s a standardized process, it’s not personal, and that makes it easier to execute,” he says.

Convenient process

The process is customer friendly. It is clear and convenient for physicians to navigate. For example, new product requests can be submitted electronically.

Timely decisions

The policy specifies how decisions will be made, and decisions are made in a timely manner.

Typically, product decisions should be made in 30 to 60 days, he says. A longer process may be needed for more complex devices such as implantables.

Join our community

Learn More
Video Spotlight
Live chat by BoldChat